K.E. MAZOVKA, A.V. TKACHEV 

Rostov State Medical University, 29 Nakhichevanskii alley, Rostov-on-Don, Russian Federation, 344022

Mazovka K.E. — Assistant Professor of Internal Diseases Propaedeutics Department, tel. (863) 271-99-15, e-mail: c.bac@rambler.ru

Tkachev A.V. — D. Med. Sc., Professor, Head of Internal Diseases Propaedeutics Department, tel. (863) 250-41-74, e-mail: tkachev@aaanet.ru

The article presents data on expression of matrix metalloproteinase-9 and tissue inhibitor of matrix metalloproteinase-1. It is established that at irritable bowel disease the MMP-9 expression is very weak, while this indicator sharply increases at ulcerative colitis. The research results also testify to the existence of reliably significant differences of MMP-9 and TIMP-1 expression during aggravation and remission stages of ulcer colitis. The obtained data prove that these indicators can be used for assessing the disease activity. 

Key words: ulcerative colitis, irritable bowel syndrome, metalloproteinases, tissue inhibitors of matrix metalloproteinase.

REFERENCES

1.  Allison M.C., Dbillou A.P., Lewis W.G., Pounder R.E. Inflammatory bowel disease. Mosby, 1998.

2.  Tkachev A.V., Mkrtchyan L.S., Nikitina K.E. Features of epidemiology and etiopathogenesis of inflammatory bowel disease: state of the problem. Nauchnaya mysl’ Kavkaza, 2001, no. 2, pp. 175-180 (in Russ.).

3.  Stange E.F.  et al.  ECCO Consensus on UC: Definitions and diagnosis. Journal of Crohn’s and Colitis, 2008, vol. 2, iss. 1, pp. 24-62.

4.  Tkachev A.V., Mkrtchyan L.S., Nikitina K.E., Volynskaya E.I. Inflammatory bowel disease: at the crossroads of problems, Prakticheskaya meditsina, 2012, vol. no. 3 (58), pp. 17-22 (in Russ.).

5.  Andreev A.I., Tertychnyy A.S., Karel G. Current approaches to the morphological diagnosis of inflammatory bowel disease on endoscopic biopsy material. Arkhiv patologii, 2011, no. 1, pp. 40-47 (in Russ.).

6.  Wang Y.D., Yan P.Y. Expression of matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 in ulcerative colitis. World J Gastroenterol, 2006, vol. 12, no. 37, pp. 6050-6053.

7.  Meijer M.J., Mieremet-Ooms M.A., van Hogezand R.A., Lamers C.B., Hommes D.W., Verspaget H.W. Role of matrix metalloproteinase, tissue inhibitor of metalloproteinase and tumor necrosis factor-alpha single nucleotide gene polymorphisms in inflammatory bowel disease. World J. Gastroenterol, 2007, vol. 13, no. 21, pp. 2960-2966.

8.  Ravi A., Garg P., Sh. V. Sitaraman. Matrix metaloproteinases in inflammatoty bowel disese: boon or bane? Inflamm Bowel Dis, 2007, vol. 13, no. 1, pp. 97-107.

9.  Pender S.L., McKenzie C., Shaida A., MacDonald T.T. Regulation of matrix metalloproteinases in human intestinal mucosa. Ann N Y Acad Sci, 1999, vol. 878, pp. 581-582.

10.  Pender S.L., Tickle S.P., Docherty A.J., Howie D., Wathen N.C., Mac-Donald T.T. A major role for matrix metalloproteinases in T cell injury in the gut. J Immunol, 1997. vol. 158, pp. 1582-1590.

11.  Baugh M.D., Perry M.J., Hollander A.P., Davies D.R., Cross S.S., Lobo A.J., Taylor C.J., Evans G.S. Matrix metalloproteinase levels are elevated in inflammatory bowel disease. Gastroenterology, 1999, vol. 117, no. 4, pp. 814-822.

12.  Brinckerhoff C.E., Matrisian L.M. Matrix metalloproteinases: a tail of a frog that became a prince. Nat. Rev. Mol. Cell Biol. 2002, pp. 207-214.

13.  McCawley L.J., Matrisian L.M. Matrix metalloproteinases: they’re not just for matrix anymore. Curr. Opin. Cell. Biol, 2001, vol. 13, pp. 534-40.

14.  Thiennu H. Vu. and Zena Werb. Matrix metalloproteinases: effectors of development and normal physiology. Genes & Development, 2000, vol. 14, pp. 2123-2133.

15.  Castaneda F.E., Walia B., Vijay-Kumar M., Patel N.R. et al. Targeted deletion of metalloproteinase 9 attenuates experimental colitis in mice: central role of epithelial-derived MMP. Gastroenterology, 2005, vol. 129, no. 6, pp. 1991-2008.